Journal reference: Tyndall, B., Gasdaska, A., Brannock, M
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Self-administration without professional guidance can lead to unintended consequences and compromise your health goals
[DOI] [PubMed] [Google Scholar] [72].Page AE, Slovis NM, Horohov DW
Effect of l-carnitine on carrageenan-induced inflammation in aged rats
Arbutin: This is a milder pigment inhibitor than hydroquinone
